Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up – Here’s Why

Autolus Therapeutics plc (NASDAQ:AUTL) gapped up before the market opened on Thursday . The stock had previously closed at $2.16, but opened at $2.24. Autolus Therapeutics shares last traded at $2.27, with a volume of 119,994 shares traded.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price for the company in a research note on Friday, November 15th. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Finally, Needham & Company LLC restated a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, January 13th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Autolus Therapeutics presently has an average rating of “Buy” and an average price target of $10.40.

Autolus Therapeutics Stock Up 5.3 %

The company has a market cap of $605.35 million, a P/E ratio of -1.88 and a beta of 2.05. The company has a fifty day moving average of $2.63 and a 200 day moving average of $3.53.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period last year, the company posted ($0.26) earnings per share. As a group, research analysts forecast that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Several large investors have recently bought and sold shares of the business. Wellington Management Group LLP lifted its holdings in shares of Autolus Therapeutics by 35.4% in the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock worth $87,919,000 after acquiring an additional 6,330,392 shares during the last quarter. FMR LLC increased its stake in Autolus Therapeutics by 44.6% during the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after purchasing an additional 5,478,706 shares in the last quarter. Armistice Capital LLC increased its stake in Autolus Therapeutics by 33.8% during the 2nd quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock valued at $21,750,000 after purchasing an additional 1,578,000 shares in the last quarter. Affinity Asset Advisors LLC increased its stake in Autolus Therapeutics by 27.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock valued at $14,964,000 after purchasing an additional 925,000 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Autolus Therapeutics by 145.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company’s stock valued at $4,663,000 after purchasing an additional 761,008 shares in the last quarter. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.